Therapeutic vaccine against DPP4 improves glucose metabolism in mice

• DOI: 10.1073/pnas.1322009111
• Publication Date: 2014-03-18T05:41:09Z
• Authors: Zhengda Pang; Hironori Nakagami; Mariana K. Osako; Hiroshi Koriyama; Futoshi Nakagami; Hideki Tomioka; Munehisa Shimamura; Hitomi Kurinami; Yoichi Takami; Ryuichi Morishita; Hiromi Rakugi
• Keywords: Male; 0301 basic medicine; Vaccines; Dipeptidyl Peptidase 4; T-Lymphocytes; Vaccination; Diet, High-Fat; Lymphocyte Activation; Diabetes Mellitus, Experimental; 3. Good health; Mice, Inbred C57BL; Disease Models, Animal; Mice; 03 medical and health sciences; Glucose; Treatment Outcome; Diabetes Mellitus, Type 2; Animals; Amino Acid Sequence; Antigens; Insulin Resistance; Peptides

Significance Type 2 diabetes mellitus (T2DM) has become a common disease, and long-term effective drugs have become a necessity. In recent years, dipeptidyl peptidase 4 (DPP4) inhibitors have been commercialized due to its ability to inhibit glucagon-like peptide 1 degradation, a hormone important for enhancing insulin secretion. Despite the availability of efficient drugs, the success of treatment is limited by patients’ inconsistent drug intake and the economic burden included in a lifelong treatment required for T2DM. To alleviate these limitations, in this study an affordable and effective immunotherapeutic method was developed and assessed for T2DM treatment. We selected and designed the appropriate peptide sequences that induce the anti-DPP4 antibody that effectively improves the diabetic phenotype without an adverse autoimmune response.